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Inhibition of COMT induces dopamine-dependent natriuresis
and inhibition of proximal tubular Na,KtATPase
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Inhibition of COMT induces dopamine-dependent natriuresis and
inhibition of proximal tubular Na,K-ATPase. The enzyme catechol-O-
methyltransferase (COMT), which plays an important role for dopamine
metabolism, is abundantly expressed in the kidney. To test whether the
natriuretic effects of dopamine may be related to the rate of dopamine
metabolism, rats were treated with nitecapone, a peripheral inhibitor of
COMT. Nitecapone, given by gavage, induced a highly significant (5.6-
told) increase in sodium excretion, which was associated with an inhibition
of the Na,K-ATPase activity in both the proximal convoluted and
proximal straight tubules (PCT and PST, respectively). These effects were
completely abolished if the rats were also treated with a specific dopamine
I antagonist, SCH 23390. Furthermore, the natriuretic effect of niteca-
pone was also observed in rats on a high salt diet. The kidney-specific
pro-drug to dopamine, glu-dopa, induced a significant, but less pro-
nounced increase in urinary sodium excretion, associated with a dopa-
mine-dependent inhibition of the Na,K -ATPase activity in the PCT but
not in the PST. Nitecapone and glu-dopa had an additive natriuretic effect.
It is concluded that COMT plays an important role in determining the
natriuretic effects of the renal dopamine system.
Several lines of evidence suggest that intrarenal dopamirie plays
a central role for the regulation of salt balance and blood pressure
[1—7]. Dopamine is produced by renal proximal tubular cells via
the uptake of filtered L-dopa. The enzyme aromatic acid decar-
boxylase (AADC), which converts L-dopa to dopamine, is present
in very high concentrations in the proximal convoluted segment of
the nephron [8, 9]. Renal dopamine can be metabolized both by
deamination via mono amino oxidase (MAO) and by methylation
via catechol-O-methyl-transferase (COMT). Dopamine formed in
renal tubular cells inhibits the activity of Na,K-ATPase, the
enzyme that yields energy to transcellular Na transport [10].
The physiological significance of the renal dopamine system
ultimately depends on its capacity to be regulated. Studies aimed
at increasing the availability of the renal dopamine precursor have
generally resulted in small, but significant natriuretic effects [11].
There is little information available on whether inhibition of renal
dopamine degradation may also influence salt excretion.
The results from several in vitro studies have suggested that in
the kidney deamination represents the major metabolic pathway
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for locally formed dopamine. In rat slices incubated with a
dopamine precursor, dihydroxyphenyl acetic acid (DOPAC) ap-
pears to be the major dopamine metabolite [12—14]. DOPAC can,
via COMT, be further metabolized to homovanillic acid (HVA).
HVA is the predominant dopamine metabolite in the urine [15].
This suggests that COMT, which is expressed in most tubular cells
[16], will also participate in the regulation of renal dopamine
availability. To test this hypothesis, rats were treated with an oral
dose of nitecapone, an inhibitor of peripheral COMT [17, 18],
and/or glu-dopa, a kidney-specific dopamine precursor [19]. Nite-
capone had a dramatic natriuretic effect. Glu-dopa had a less
pronounced, but still significant, natriuretic effect that was addi-
tive to that of nitecapone. Nitecapone inhibited Na ,K-ATPase
activity in proximal convoluted (PCT) and straight tubules (PST).
Both the natriuretic and the Na,K-ATPase inhibitory effects
were reversed in the presence of a dopamine 1 (D1) antagonist.
The results highlight the role for dopamine in the regulation of
salt metabolism, and support the concept that the natriuretic
effect of dopamine is mediated via an inhibition of tubular
Na ,K-ATPase.
METHODS
Animals
The study was performed on male Sprague-Dawley rats aged 40
to 50 days (B&K Universal, Sollentuna, Sweden) and weighing
200 to 250 g. If not otherwise indicated, the rats received standard
chow (Beaky, Fixed Formula; Bantin & Kingman Ltd., UK) and
had free access to tap water. In one protocol, the rats received
high salt (HS) diet by substituting drinking water with 0.9% NaCI
for one week.
Seven types of protocols were used: group 1, rats received
normal salt (NS) diet and vehicle; group 2, rats received the NS
diet and nitecapone; group 3, rats received the NS diet and
nitecapone in combination with a dopamine I (Dl) antagonist,
SCH 23390; group 4a and 4b, rats received a high salt (HS) diet
and nitecapone or vehicle; group 5, rats received the NS diet and
glu-dopa; group 6, rats received the NS diet and glu-dopa in
combination with nitecapone; group 7, rats received the NS diet
and glu-dopa in combination with nitecapone and SCH 23390.
Nitecapone was diluted in standard phosphate buffer, pH 8.5, and
was given by gavage as a single dose of 30 mg/kg body wt.
Glu-dopa was administered i.v. 50 jig/kg body wt/min. In the
protocol using SCH 23390, the drug was given as an i.v. infusion,
30 ,irg/kg body wt/hr, started 15 minutes before the administration
of nitecapone and glu-dopa.
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Assay of COMT activity in rat renal cortex
COMT activity was measured in rat kidney from control rats
and rats treated with a single dose of nitecapone, 30 mg/kg body
wt, given one hour before the rats were sacrificed. The rats were
anaesthetized and the kidneys were rapidly removed. COMT
activity was determined as described [20]. The renal cortex was
homogenized using a Potter-Elvehjem homogenizer in 4 volumes
of a cold solution, containing (in mM) 10 Na2HPO4 and 0.5 DII
at pH 7.4. The homogenates were centrifuged at 15,000 x g for 20
minutes. The supernatants were centrifuged at 100,000 X g for 60
minutes, and the high-speed supernatants were used to determine
the s-COMT activity. The high-speed precipitate was suspended
in the buffer and recentrifuged at 100,000 x g for 60 minutes. The
procedure was repeated and the washed pellet was used for the
determination of m-COMT activity. The reaction mixture for
s-COMT contained in a total volume of 250 1u1: 50 .d of 0.1 M
sodium phosphate buffer, pH 7.8, 25 jd of 50 m magnesium
chloride, 50 d of 1 mtvt S-adenosyl-L-methionine (SAM), 25 to
100 j.d of the COMT preparation, (25 fil of test compounds for
1C50 determinations) and 25 1d of 4 mtvi DHABC. The reaction
mixture for m-COMT contained: phosphate buffer pH 7.4, 100 itl
of m-COMT suspension and 25 1a1 of 1 mrvt DHABC. Other
ingredients were the same. After a 30 minute incubation at 37°C,
the reactions were terminated by the addition of 4 M perchiorid
acid. The precipitated protein was removed by centrifugation and
the O-methylated reaction products were determined by the use
of HPLC with electrochemical detection. Chromatography was
performed in 5 jim Sperisorb ODS column (4.6 mm x 150 mm)
fitted with a precolumn. The elution buffer contained 0.1 M
sodium phosphate and 0.15 mivi EDTA, pH 3.2, in 22% methanol.
The flow rate was 1.5 mI/mm. The detection was carried out with
a glassy carbon electrode using +0.9 V potential against Ag/AgCl
reference electrode. The sensitivity was 10 nA. The protein
concentrations were determined using a Bio-Rad protein assay
kit. BSA was used as a standard.
Renal function
At the day of experiment, the rats were anaesthetised with
Inactin-Byk (Byk-Gulden, Konstanz, Germany) 80 mg/kg body wt
i.p. Tracheotomy was performed to assure free airways during the
experiment. Both jugular veins were catheterized for infusion and
one carotid artery for pressure recording and blood sampling.
Both ureters were catheterized with thin polyethylene tubing for
urine collection, Blood pressure was recorded via a Statham
transducer connected to a Grass 7B polygraph throughout the
experiment.
The renal function studies, performed during euvolemic condi-
tion, were carried out as described [211. To determine the
glomerular filtration rate (GFR), 5% solution of mutest (Lae-
vosan, Gcsellschaft, Linz, Austria) diluted in Ringer's solution
was infused via a constant infusion pump in a dose of 1% of body
wt/hr. This infusion rate maintains the hematocrit stable during
the experiment. The infusion was preceded by a holus dose, 1% of
body wt. Following a priming period of one hour, urine collection
was started. Two 20-minute control collection periods were
followed by drug administration. Forty-five minutes after admin-
istration of the drugs, two consecutive 20-minute periods of urine
collection were made. The mean values from the two control
periods and two experimental periods were used for further
calculations. Plasma and urine were analyzed for inulin [22].
Sodium was analyzed with a flame photometer (Eppendorf 6524,
Hamburg, Germany).
Preparation of proximal tubule segments
Kidney perfusion and tubule microdissection were performed
as described [23]. The rats were anaesthetised with an intraperi-
toneal injection of sodium barbital (Mebumal vet; Nord Vacc,
Stockholm, Sweden) 5 to 6 mg per 100 g body wt. Following a
midline incision, the left kidney was exposed and perfused with a
cold, modified Hanks' solution, containing 0.05% collagenase
(Sigma Chemical Co., St. Louis, MO, USA) and 0.1% bovine
serum albumin (BSA; Behringwerke, Marburg, Germany). The
pH was adjusted to 7.4. The kidney was removed and cut along its
corticopapillary axis into small pyramids that were incubated for
20 minutes at 35°C in the perfusion solution containing i0 M
butyrate to optimize mitochondrial respiration [241. The solution
was continuously bubbled with oxygen. After incubation, the
tissue was rinsed with the modified Hanks' solution devoid of
collagenase and BSA and with a CaC12 concentration of 0.25 mivi
(microdissection solution).
Single proximal convoluted or straight tubular segments were
manually dissected (tubular segment length 0.4 to 1.1 mM) under
a stereo microscope at 4°C. The tubule segments were individually
transferred to the concavity of a bacteriological slide in a drop of
the microdissection solution and photographed for length deter-
mination in an inverted microscope at 100 x magnification.
Tubules were stored on ice until dissection was completed, at
most for 30 to 60 minutes.
Tubules from control and drug-treated animals were all incu-
bated for 10 minutes at room temperature in I pd of microdissec-
tion solution, without any drugs added except for the experiment
where the dopamine 1-receptor (D1) antagonist SCH 23390, i0"
M, was used.
Determination of Na,KtATPase activity
The preincubation period was stopped by placing the tubular
segments at 4°C. The segments were made permeable by a rapid
hypotonic shock and freezing and thawing. This procedure allows
ATP and sodium free access to the interior of the cell. They were
incubated at 37°C for 15 minutes in a medium containing (in mM):
70 NaCl, 5 KCI, 10 MgCI2, I EGTA, 100 Tris-HCI, 10 Tris-ATP,
and [y32P] ATP (NEN, Boston, MA, USA); 2 to 5 Ci mmoL' in
tracer amounts (5 nCi/ml) in the absence or presence of 2 ms
ouabain (USB, Cleveland, OH, USA). For determination of
ouabain-insensitive ATPase activity NaCI and KCI were omitted
and Tris-HC1 was 150 m. The 12P-phosphate liberated by
hydrolysis of ATP was separated by filtration through a Millipore
filter after absorption of the unhydrolyzed nucleotide on activated
charcoal and radioactivity was counted in a liquid scintillation
spectrometer.
In each study, total ATPase activity and ouabain-insensitive
ATPase activity was measured on each of five to eight tubule
segments. Na' ,K-ATPase activity (pmol of 32P, hydrolyzed per
mm of tubule per hour) was calculated as the difference between
the mean value for total ATPase and ouabain-insensitive ATPase
activity, and expressed as absolute value.
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Fig. 1. Effect of nitecapone on sodium excretion. A single gastric dose of
the peripheral COMT inhibitor, nitecapone, 30 mg/kg body wt, induces a
5.6-fold increase in the rate of sodium excretion. This natriuretic response
is completely abolished after pre-treatment with a specific dopamine I
antagonist, SCH 23390. Values are means SEM and are expressed as
mmol urinary sodium excreted/mm. Each data point represents the
average from 10 animals. *p < 0.001 versus control. P < 0.01 versus
nitecapone alone.
Statistics
Values are expressed as mean SEM. Statistical analysis was
performed with Student's t-test and analysis of variance by using
ANOVA, Dunett's method. A value of P < 0.05 was considered
significant.
RESULTS
In order to study the renal effects of COMT inactivation, rats
were given nitecapone, a peripheral COMT inhibitor, by gavage,
30 mg/kg body wt. The efficacy of this procedure was tested by
determination of the activity of COMT in kidneys removed 30 to
45 minutes after nitecapone administration. At that time the
COMT activity (pmol/min/mg protein) was 58 14 compared to
846 95 in kidneys from vehicle treated rats. The inhibitory effect
of nitecapone on the activity of COMT in the kidney is expected
to last for three to four hours. The major metabolite of dopamine
is HVA. Rats treated with nitecapone had a lower HVA/creati-
nine ratio (jIM/mM) in the urine than control rats (1.15 0.48 vs.
3.53 0.44, P < 0.01).
Rats that received nitecapone had a significantly higher rate of
sodium excretion (jimollmin) than untreated rats (nitecapone
1.69 0.27 vs. control 0.30 0.06; Fig. 1). In rats treated with a
specific Dl antagonist, SCH 23390, the natriuretic effect of
nitecapone was completely abolished. The fractional excretion of
sodium (% of filtered sodium excreted in urine) was also signifi-
cantly higher in the nitecapone treated rats than in the control rats
(0.60 0.17 vs. 0.17 0.05, P < 0.001). SCH 23390 was given
intravenously and the infusion was started 15 minutes before
nitecapone administration. Rats that were treated only with SCH
23390 had a similar sodium excretion (0.29 0.06 jtmol/min) as
control rats.
Infusion of glu-dopa, 50 j.g/kg body wt/min, also significantly
increased urinary sodium excretion (control 0.30 0.06 vs.
glu-dopa 0.68 0.07 J.LmoI/min). The natriuretic effect of glu-
#
-I-
3.5 -
3-
2.5
2-
1.5
1
0.5
0
Ea
>
z
*I
Table 1. Results of the three study protocols
Control Glu-dopa Nitecapone
V mI/mm 0.010 0.001 0.009 0.001 0.023 0.010
GFR mi/mm 1.91 0.32 1.96 0.35 1.84 0.23
MAP mm Hg 120 4 126 7 129 8
0
Nitecapone
SCH 23390
Glu-dopa
.ri rLi ri
— + + + +
— — .- + +
dopa was however much less pronunced than that of nitecapone.
Glu-dopa and nitecapone had an additive effect on sodium
excretion. This effect was also abolished when the Dl antagonist
was pre-administered. (control 0.3 0.02; glu-dopa and niteca-
pone 2.5 0.5; glu-dopa, nitecapone and SCH 23390, 0.3 0.02
— — + +
mol/min).
Treatment with nitecapone and/or glu-dopa did not significantly
alter GFR, mean arterial blood pressure (MAP) or diuresis (V)
(Table 1).
The natriuretic effect of nitecapone was also observed in rats on
high salt (HS) diet. The HS rats, as expected, had a higher basal
sodium-excretion than rats fed with a normal salt diet (NS 0.30
0.02 vs. HS 1.87 0.85 tmol/min, N = 10, P < 0.001). Following
nitecapone treatment, sodium excretion in the HS group was
4.82 0.74 mol/min (N = 10, P < 0.001).
There is evidence that the enzymes responsible for metabolism
and synthesis of intrarenal dopamine are differentially expressed
in the nephron. In situ hybridization studies have demonstrated
that COMT mRNA is expressed in most tubular segments but the
signal is particularly strong in the straight part of the proximal
tubule, PST [161. In contrast, the expression of AADC, the L-dopa
converting enzyme, appears to be restricted to the proximal
tubules and mainly to the convoluted part, PCT [5, 8, 9]. The
activity of AADC is considerably higher in the PCT than in the
PST and very low or non-detectable in all other tubular segments
[251. In this study the effects of in vivo administration of niteca-
pone and glu-dopa on proximal tubular Na,K-ATPase activity
was measured in both PCT and PST. In PCT segments Na,K-
ATPase activity was significantly lower in nitecapone treated rats
than in simultaneously studied control rats (Fig. 2A). This appar-
ent inhibition was completely abolished by the D1 antagonist,
SCH 23390 (control 2211 108; nitecapone 1568 167; niteca-
pone and SCH 23390, 2153 226 pmol Pi/mM tubule/hr). SCH
23390 was administered intravenously 15 minutes prior to niteca-
pone and was present during the preparation of the tubules at a
concentration of IO M. Treatment with SCH 23390 alone had no
effect on PCT NatK-ATPase activity (2142 277 pmol Pi/mM
tuhule/hr, N = 4). Glu-dopa also significantly inhibited PCT
Na,K-ATPase activity (control 2211 108; glu-dopa 1159 97
pmol Pi/mM tubule/hr). SCH 23390 abolished the inhibitory effect
of glu-dopa (glu-dopa and SCH 23390, 2034 268 pmol Pi/mM
tubule/hr; Fig. 2B). In PST segments, nitecapone inhibited the
Na,K1-ATPase activity to an even larger extent than in PCT
segments (57 5% of control; Fig. 3). In contrast, glu-dopa
treatment had no effect on Na,K-ATPase activity in PST
segments (control 2225 185 vs. glu-dopa 2272 165 pmol
Pi/mM tubule/hr). We have no explanation for why glu-dopa had
no effect in PST. It is possible either that the concentration of
AADC and formation of dopamine is very low in this segment, or
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Fig. 3. Effects of nitecapone on the Na,K-ATPase activity of single
PST segments. A single gastric dose of the peripheral COMT inhibitor,
nitecapone, 30 mg/kg body wt, significantly inhibits the activity of PST
Na,K-ATPase. Values are means SCM and are expressed as pmol
Pi/mM tubule/hr. Each data point represents the average from 5 experi-
ments. *p < 0.05 versus control.
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Fig. 2. A. Effects of nitecapone on the Na,KtATPase activity of single
PCT segments. A single gastric dose of the peripheral COMT inhibitor,
nitecapone, 30 mg/kg body wt, significantly inhibits the activity of PCT
Na,K-ATPase. This effect is completely abolished after pre-treatment
with the dopamine I antagonist, SCH 23390. Values are means SCM and
are expressed as pmol Pi/mM tubule/hr. Each data point represents the
average from 5 experiments. *JJ < 0.05 versus control. NS, not significant
versus control. B. Effects of glu-dopa on the Na,K-ATPase activity of
single PCT segments. A 30 minutes infusion with glu-dopa, 50 jrg/kg body
wt/min, significantly inhibits the activity of PCT Na,K-ATPase. This
effect is completely abolished after pre-treatment with the dopamine I
antagonist, SCH 23390. Values are means SCM and are expressed as
pmol Pi/mM tubule/hr. Each data point represents the average from 6 resp.
4 experiments. P < 0.05 versus control; NS, not significant versus control.
that the concentration of y-glutamyl transferase is so low that
glu-dopa will not enter the PST cells.
DISCUSSION
Several lines of evidence suggest that endogenous dopamine
plays an important role for the regulation of salt metabolism
[reviewed in 1]. This concept is confirmed by the present study.
Inhibition of dopamine degradation as well as treatment with a
dopamine precursor increased sodium excretion and inhibited the
activity of proximal tubule Na,K-ATPase. Both these effects
were abolished by a D1 antagonist.
+ +
CQMT
3-MTDOPAC /
HVA
Fig. 4. Major pathways for peripheral dopamine degradation. Abbrevi-
ations are: MAO, monoamino oxidase; COMT, catechol-O-methyl trans-
ferase; DOPAC, dihydroxyphenyl acetic acid; 3-MT, 3-methoxytyramine;
HVA, homovanillic acid.
Renal dopamine is inactivated via two major pathways, both
involving MAO and COMT. The common end-metabolite in
these degradation pathways is HVA (Fig. 4). The MAO activity in
renal tissue is high [26, 271 and several studies have suggested that
MAO may be of importance for the modulation of the renal
dopamine effects. The COMT activity in renal tissue is also very
high [28 —301. The results from this study demonstrate that COMT
does play a significant role for the regulation of dopamine
dependent functions of the kidney.
COMT is a ubiquitous enzyme occurring in plants, microorgan-
isms and animals [18]. In mammals COMT is distributed through-
out various organs [28—30]. COMT catalyzes the transfer of a
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methyl group from S-adenosyl-L-methionine to the m-hydroxy
group of various catecholamines. The O-methylation reaction is
important in the enzymatic inactivation of catecholamines [17,
18]. Nitecapone is a specific inhibitor of the O-methylation.
Although like all substances with a catechol structure, including
norepinephrine, L-dopa and dopamine [30, 31] can be substrates
for nitecapone, the finding that the effects induced by nitecapone
were reversed by a dopamine receptor antagonist does indicate
that the dominant renal effect of nitecapone is to increase the
renal dopamine torius.
y-L-glutamyl-L-dopa (glu-dopa) is a kidney specific pro-drug
for dopamine [191. Glu-dopa is converted to L-dopa by y-glutamyl
transferase, which is present in high concentrations in the apical
cell membrane of renal proximal tubular cells. In accordance with
previous studies [ii], it was found that glu-dopa induced a
moderate increase in sodium excretion. Treatment with glu-dopa
together with nitecapone induced an additive, dopamine-depen-
dent increase of sodium excretion indicating that both the forma-
tion and the degradation of dopamine may influence the tonic
renal effects of this catecholamine.
The natriuretic response to nitecapone and glu-dopa was
associated with an inhibition of proximal tubular Na,K-
ATPase. Inhibition of COMT, which is present in most tubular
segments, but particularly abundant in PST [16], reduced the
activity of Na,K -ATPase in both PCT and PST segments, and
this was associated with a more than fivefold increase in urinary
sodium excretion rate. Treatment with glu-dopa inhibited
Na,K-ATPase in PCT but not in PST and had a less pro-
nounced effect on sodium excretion than nitecapone. The results
support the concept that regulation of tubular Na,K-ATPase
plays an important role in determining sodium excretion. Taken
together, these findings suggest that manipulations aimed at
increasing the renal dopamine tonus have a natriuretic effect.
Salt-sensitive essential hypertension is associated with reduced
dopamine availability [32—34], and drugs that increase the renal
dopaminergic tonus and enhance dopamine induced natriuresis
have therefore been searched for extensively; however, to date
dopamine agonists that can he orally administered are not avail-
able. Dopamine precursors have only a moderate effect on sodium
excretion, probably due to dopamine degradation. The present
study, demonstrating a pronounced natriuretic effect by an orally
administered, peripheral inhibitor of dopamine inactivation may
therefore suggest a new principle in the therapy of salt-sensitive
hypertension.
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